AU2020394255B2 - Long-acting GDF15 fusion protein and pharmaceutical composition comprising same - Google Patents

Long-acting GDF15 fusion protein and pharmaceutical composition comprising same

Info

Publication number
AU2020394255B2
AU2020394255B2 AU2020394255A AU2020394255A AU2020394255B2 AU 2020394255 B2 AU2020394255 B2 AU 2020394255B2 AU 2020394255 A AU2020394255 A AU 2020394255A AU 2020394255 A AU2020394255 A AU 2020394255A AU 2020394255 B2 AU2020394255 B2 AU 2020394255B2
Authority
AU
Australia
Prior art keywords
seq
gdf15
amino acid
hole
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020394255A
Other languages
English (en)
Other versions
AU2020394255A1 (en
Inventor
Hyun Ho Choi
Wonee Chong
Mi Kyeong Ju
Junhwan Kim
Sukyung KIM
Won Tae Kim
Youn Woo Lee
Seyoung LIM
Young Bong Park
Bo Ra SIM
Ji Eun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AU2020394255A1 publication Critical patent/AU2020394255A1/en
Application granted granted Critical
Publication of AU2020394255B2 publication Critical patent/AU2020394255B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020394255A 2019-11-26 2020-11-25 Long-acting GDF15 fusion protein and pharmaceutical composition comprising same Active AU2020394255B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190153680 2019-11-26
KR10-2019-0153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
AU2020394255A1 AU2020394255A1 (en) 2022-06-09
AU2020394255B2 true AU2020394255B2 (en) 2026-08-06

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394255A Active AU2020394255B2 (en) 2019-11-26 2020-11-25 Long-acting GDF15 fusion protein and pharmaceutical composition comprising same

Country Status (11)

Country Link
US (1) US20230002460A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065597A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023503472A (cg-RX-API-DMAC7.html)
KR (1) KR20210065057A (cg-RX-API-DMAC7.html)
CN (1) CN114729020A (cg-RX-API-DMAC7.html)
AU (1) AU2020394255B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010227A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161302A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006173A (cg-RX-API-DMAC7.html)
WO (1) WO2021107603A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204624B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160120999A1 (en) * 2014-10-31 2016-05-05 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
EP1861419B1 (en) * 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
CA2899170C (en) * 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
WO2015197446A1 (en) * 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) * 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
US20160120999A1 (en) * 2014-10-31 2016-05-05 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders

Also Published As

Publication number Publication date
EP4065597A4 (en) 2024-01-24
CA3161302A1 (en) 2021-06-03
CN114729020A (zh) 2022-07-08
JP2023503472A (ja) 2023-01-30
EP4065597A2 (en) 2022-10-05
MX2022006173A (es) 2022-06-14
WO2021107603A2 (en) 2021-06-03
WO2021107603A3 (en) 2021-07-15
ZA202204624B (en) 2023-11-29
KR20210065057A (ko) 2021-06-03
BR112022010227A2 (pt) 2022-09-13
US20230002460A1 (en) 2023-01-05
AU2020394255A1 (en) 2022-06-09